Mar 17, 2017 - Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Mar 15, 2017 - Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.
Mar 15, 2017 - The following slide deck was published by Allergan plc in conjunction with this event.
Mar 13, 2017 - U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.
Mar 13, 2017 - Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
Mar 10, 2017 - Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
Mar 09, 2017 - Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Mar 08, 2017 - Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Mar 08, 2017 - President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Feb 27, 2017 - Pharma Industry Outlook - February/March 2017